• Benitec annual report highlighted progress for BB-301 in OPMD-related dysphagia, with Cohort 1 follow-up completed.
• Cohort 2 enrollment finished, with three high-dose patients treated without safety issues reported.
• FDA Type C meeting held in 3Q2026 to align on pivotal study design; minutes expected in October.
• Interim Phase 1b/2a data slated for late-breaking presentation at ESGCT on Oct. 27-30, 2026.
• Pivotal BB-301 trial initiation targeted for mid-2027; cash position of USD 180 million cited as supporting execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609141600PRIMZONEFULLFEED9826115) on September 14, 2026, and is solely responsible for the information contained therein.